ciprofloxacin has been researched along with Pyelonephritis in 79 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Pyelonephritis: Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This phase II clinical study compared the efficacies and safeties of finafloxacin and ciprofloxacin in patients with complicated urinary tract infection and/or pyelonephritis." | 9.27 | Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections. ( Bentley, C; Dalhoff, A; Fischer, C; Lückermann, M; Naber, K; Nowicki, M; Vente, A; Wagenlehner, F; Wohlert, S, 2018) |
| "In a prospective, non-inferiority trial undertaken at 21 centres of infectious diseases in Sweden, women (aged ≥18 years) who were not pregnant and had a presumptive diagnosis of acute pyelonephritis were randomly assigned to oral treatment with ciprofloxacin 500 mg twice daily for 7 days or 14 days." | 9.16 | Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. ( Ekman, GS; Hermansson, AB; Kahlmeter, G; Kuylenstierna, N; Lannergård, A; Otto, G; Sandberg, T; Settergren, B; Skoog, G, 2012) |
| "A clinical study was conducted to compare the efficacy and safety of levofloxacin 750 mg once daily for 5 days to ciprofloxacin twice daily for 10 days for the treatment of complicated urinary tract infections (cUTI) or acute pyelonephritis (AP)." | 9.13 | A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. ( Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Peterson, J, 2008) |
| "A double-blind, noninferiority trial was conducted to establish the safety and efficacy of a once-daily, 5-day course of levofloxacin 750 mg compared to a twice-daily, 10-day course of ciprofloxacin in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)." | 9.12 | A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. ( Brown, P; Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Klausner, HA; Peterson, J, 2007) |
| "We assessed the efficacy and safety of 1,000 mg extended release ciprofloxacin orally once daily vs conventional 500 mg ciprofloxacin orally twice daily, each for 7 to 14 days, in patients with a complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis (AUP)." | 9.11 | Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. ( Church, DA; Klimberg, IW; Kowalsky, SF; Nicolle, LE; Song, J; Talan, DA, 2004) |
| "This study compared the clinical and bacteriologic efficacy and tolerability of gatifloxacin versus ciprofloxacin in adult patients with complicated UTIs or pyelonephritis." | 9.10 | A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. ( Auerbach, SM; Brown, GL; Cox, CE; Fox, BC; Marbury, TC; Pittman, WG; Yang, JY, 2002) |
| "Administration of a dose of tobramycin did not demonstrate its clinical benefit in treatment of acute uncomplicated pyelonephritis treated by oral ciprofloxacin." | 9.09 | [Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin]. ( Baron, D; Bonnieux, J; Bourrier, P; Le Conte, P; Lebrin, P; Merit, JB; Potel, G; Simon, N, 2001) |
| "To evaluate, in two randomized, multicenter trials, levofloxacin compared with ciprofloxacin and lomefloxacin for efficacy and safety in treating acute pyelonephritis." | 9.08 | Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. ( Callery-D'Amico, S; Fowler, CL; Kim, SS; Klimberg, IN; Richard, GA, 1998) |
| "Rufloxacin once daily is a good alternative in the outpatient treatment of acute uncomplicated pyelonephritis." | 9.08 | Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis. ( Bach, D; Cesana, M; Hübner, A; Plétan, Y; van Breukelen, G; van den Berg-Segers, A, 1995) |
| "A prospective, randomised trial was undertaken to compare the efficacy of ciprofloxacin and netilmicin for the treatment of acute pyelonephritis." | 9.07 | Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis. ( Bailey, RR; Lynn, KL; Peddie, BA; Robson, RA; Smith, A, 1992) |
| "Our findings suggest that 7 days of TMP-SMX therapy may result in similar clinical outcomes compared with 7 days of ciprofloxacin for the treatment of pyelonephritis." | 7.85 | A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis. ( Conley, AT; Fox, MT; Melia, MT; Same, RG; Tamma, PD, 2017) |
| "The study investigated the in vitro, ex vivo and in vivo efficacy of ajoene and ciprofloxacin (CIP) alone and in combination against Pseudomonas aeruginosa biofilms and biofilm-associated murine acute pyelonephritis." | 7.83 | Exploiting the antivirulence efficacy of an ajoene-ciprofloxacin combination against Pseudomonas aeruginosa biofilm associated murine acute pyelonephritis. ( Chhibber, S; Harjai, K; Saini, H; Vadekeetil, A, 2016) |
| "The aim of this study was to evaluate the efficiency of methylene blue (MB) in preventing renal scar formation after the induction of pyelonephritis (PNP) in a rat model with delayed antimicrobial therapy." | 7.74 | The effects of methylene blue on renal scarring due to pyelonephritis in rats. ( Aksu, B; Aydin, S; Ayvaz, S; Durmus-Altun, G; Gurcan, S; Inan, M; Kanter, M; Oz Puyan, F; Pul, M; Uzun, H, 2007) |
| "This study aimed to evaluate the efficacy and safety of oral antibacterial treatment with fluoroquinilone for acute uncomplicated pyelonephritis Thirteen female patients with acute uncomplicated pyelonephritis were treated with oral fluoroquinilone (ciprofloxacin; CPFX)." | 7.71 | Efficacy of a 14-day course of oral ciprofloxacin therapy for acute uncomplicated pyelonephritis. ( Hirose, T; Hisasue, SI; Itoh, N; Kato, R; Kunishima, Y; Matsukawa, M; Satoh, T; Shimizu, T; Takagi, S; Takahashi, S; Tsukamoto, T, 2001) |
| "The influence of fever on the pharmacokinetics of ciprofloxacin was investigated in seven patients with acute febrile diseases." | 7.70 | Influence of fever on the pharmacokinetics of ciprofloxacin. ( Belic, A; Beovic, B; Grabnar, I; Karba, R; Marolt-Gomiscek, M; Mrhar, A; Zupancic, T, 1999) |
| " In a murine model of hematogenous pyelonephritis, the in vivo efficacies of levofloxacin and ciprofloxacin were evaluated against two methicillin-susceptible and two methicillin-resistant S." | 7.69 | In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains. ( Barrett, JF; Frosco, MB; Kulwich, BA; Licata, L; Melton, JL; Stewart, FP, 1996) |
| "We report a 67 years old diabetic female that received ciprofloxacin for an acute pyelonephritis." | 7.69 | [Tenosynovitis caused by ciprofloxacin. Clinical case]. ( Guzmán, L; Lara, R; Wainstein, E, 1994) |
| "The ciprofloxacin efficacy was compared to that of tobramycin in an Escherichia coli pyelonephritis model in rat." | 7.68 | Treatment of experimental Escherichia coli pyelonephritis in rat by ciprofloxacin in comparison with tobramycin. ( Grise, G; Le Boete, I; Lecomte, F; Lemeland, JF; Thauvin-Eliopoulos, C, 1990) |
| "As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study." | 7.68 | Treatment of urinary tract infections with ciprofloxacin after renal transplantation. ( Alivanis, P; Dioudis, C; Grekas, D; Thanos, V; Tourkantonis, A, 1993) |
| "Two quinolones, fleroxacin and ofloxacin were used as oral treatment in a model of experimental pyelonephritis in rats." | 7.67 | Comparative studies of fleroxacin and ofloxacin in experimental pyelonephritis. ( Ritzerfeld, W, 1988) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial." | 6.71 | Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. ( Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P, 2004) |
| "Sulopenem followed by oral sulopenem-etzadroxil/probenecid was not noninferior to ertapenem followed by oral step-down therapy for the treatment of cUTIs, driven by a lower rate of asymptomatic bacteriuria in those who received ciprofloxacin." | 5.69 | Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial. ( Akinapelli, K; Aronin, SI; Breen, J; Das, AF; Dunne, MW; Puttagunta, S; Zelasky, MT, 2023) |
| "Ciprofloxacin was stopped and her pain quickly resolved." | 5.40 | Ciprofloxacin-induced tendinopathy of the gluteal tendons. ( Aronowitz, P; Shimatsu, K; Sim, H; Subramaniam, S, 2014) |
| "Treatment by ciprofloxacin (15 mg." | 5.29 | Suppression of renal scarring by prednisolone combined with ciprofloxacin in ascending pyelonephritis in rats. ( Haraoka, M; Kubo, S; Kumazawa, J; Matsumoto, T; Takahashi, K; Tanaka, M, 1994) |
| " This phase II clinical study compared the efficacies and safeties of finafloxacin and ciprofloxacin in patients with complicated urinary tract infection and/or pyelonephritis." | 5.27 | Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections. ( Bentley, C; Dalhoff, A; Fischer, C; Lückermann, M; Naber, K; Nowicki, M; Vente, A; Wagenlehner, F; Wohlert, S, 2018) |
| "Ciprofloxacin was tested in the acute and chronic experimental E." | 5.27 | [Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats]. ( Boness, J; Marre, R; Schulz, E; Tietgen, K, 1986) |
| "In a prospective, non-inferiority trial undertaken at 21 centres of infectious diseases in Sweden, women (aged ≥18 years) who were not pregnant and had a presumptive diagnosis of acute pyelonephritis were randomly assigned to oral treatment with ciprofloxacin 500 mg twice daily for 7 days or 14 days." | 5.16 | Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. ( Ekman, GS; Hermansson, AB; Kahlmeter, G; Kuylenstierna, N; Lannergård, A; Otto, G; Sandberg, T; Settergren, B; Skoog, G, 2012) |
| "A clinical study was conducted to compare the efficacy and safety of levofloxacin 750 mg once daily for 5 days to ciprofloxacin twice daily for 10 days for the treatment of complicated urinary tract infections (cUTI) or acute pyelonephritis (AP)." | 5.13 | A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. ( Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Peterson, J, 2008) |
| "A double-blind, noninferiority trial was conducted to establish the safety and efficacy of a once-daily, 5-day course of levofloxacin 750 mg compared to a twice-daily, 10-day course of ciprofloxacin in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)." | 5.12 | A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. ( Brown, P; Fisher, AC; Kahn, JB; Kaul, S; Khashab, M; Klausner, HA; Peterson, J, 2007) |
| "We assessed the efficacy and safety of 1,000 mg extended release ciprofloxacin orally once daily vs conventional 500 mg ciprofloxacin orally twice daily, each for 7 to 14 days, in patients with a complicated urinary tract infection (cUTI) or acute uncomplicated pyelonephritis (AUP)." | 5.11 | Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. ( Church, DA; Klimberg, IW; Kowalsky, SF; Nicolle, LE; Song, J; Talan, DA, 2004) |
| "This study compared the clinical and bacteriologic efficacy and tolerability of gatifloxacin versus ciprofloxacin in adult patients with complicated UTIs or pyelonephritis." | 5.10 | A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. ( Auerbach, SM; Brown, GL; Cox, CE; Fox, BC; Marbury, TC; Pittman, WG; Yang, JY, 2002) |
| "Administration of a dose of tobramycin did not demonstrate its clinical benefit in treatment of acute uncomplicated pyelonephritis treated by oral ciprofloxacin." | 5.09 | [Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin]. ( Baron, D; Bonnieux, J; Bourrier, P; Le Conte, P; Lebrin, P; Merit, JB; Potel, G; Simon, N, 2001) |
| " They were compared with 23 acute pyelonephritis patients given ciprofloxacin in a dose 1 g/day." | 5.09 | [Tavanik effectiveness and safety in the treatment of urinary tract infection complications]. ( Loran, OB; Pushkar', DIu; Rasner, PI, 2001) |
| "Rufloxacin once daily is a good alternative in the outpatient treatment of acute uncomplicated pyelonephritis." | 5.08 | Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis. ( Bach, D; Cesana, M; Hübner, A; Plétan, Y; van Breukelen, G; van den Berg-Segers, A, 1995) |
| "To evaluate, in two randomized, multicenter trials, levofloxacin compared with ciprofloxacin and lomefloxacin for efficacy and safety in treating acute pyelonephritis." | 5.08 | Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. ( Callery-D'Amico, S; Fowler, CL; Kim, SS; Klimberg, IN; Richard, GA, 1998) |
| "A prospective, randomised trial was undertaken to compare the efficacy of ciprofloxacin and netilmicin for the treatment of acute pyelonephritis." | 5.07 | Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis. ( Bailey, RR; Lynn, KL; Peddie, BA; Robson, RA; Smith, A, 1992) |
| " The duration of treatment for uncomplicated pyelonephritis can be safely shortened to 7 days when using ciprofloxacin." | 4.89 | [Infectious diseases]. ( Malinverni, R; Pittet, R, 2013) |
| "Our findings suggest that 7 days of TMP-SMX therapy may result in similar clinical outcomes compared with 7 days of ciprofloxacin for the treatment of pyelonephritis." | 3.85 | A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis. ( Conley, AT; Fox, MT; Melia, MT; Same, RG; Tamma, PD, 2017) |
| "The study investigated the in vitro, ex vivo and in vivo efficacy of ajoene and ciprofloxacin (CIP) alone and in combination against Pseudomonas aeruginosa biofilms and biofilm-associated murine acute pyelonephritis." | 3.83 | Exploiting the antivirulence efficacy of an ajoene-ciprofloxacin combination against Pseudomonas aeruginosa biofilm associated murine acute pyelonephritis. ( Chhibber, S; Harjai, K; Saini, H; Vadekeetil, A, 2016) |
| "According to Norwegian guidelines for antibiotic use in primary care, ciprofloxacin is reserved for complicated urinary tract infections (UTI)." | 3.80 | A simple intervention to reduce inappropriate ciprofloxacin prescribing in the emergency department. ( Berild, D; Fagan, M; Lindbæk, M; Reiso, H, 2014) |
| "Discordant empirical therapy, mostly with ciprofloxacin, leads to worse early clinical response and longer hospital stay than concordant therapy in community-acquired bacteremic acute pyelonephritis, although it does not affect on overall mortality or clinical cure rate." | 3.77 | Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. ( Chung, DR; Kim, Y; Lee, SS, 2011) |
| "The aim of this study was to evaluate the efficiency of methylene blue (MB) in preventing renal scar formation after the induction of pyelonephritis (PNP) in a rat model with delayed antimicrobial therapy." | 3.74 | The effects of methylene blue on renal scarring due to pyelonephritis in rats. ( Aksu, B; Aydin, S; Ayvaz, S; Durmus-Altun, G; Gurcan, S; Inan, M; Kanter, M; Oz Puyan, F; Pul, M; Uzun, H, 2007) |
| "The prevalence of hemolysin, type 1 fimbriae, P fimbriae, cytotoxic necrotizing factor-1 (CNF-1), aerobactin, and autotransporter toxin (sat) was analyzed by polymerase chain reaction and phenotypic assays of 42 epidemiologically unrelated Escherichia coli strains causing acute pyelonephritis in women (21 nalidixic acid-susceptible and 21 nalidixic acid-resistant strains) and 58 E." | 3.71 | Are quinolone-resistant uropathogenic Escherichia coli less virulent? ( Barranco, M; Horcajada, JP; Mensa, J; Moreno, A; Ruiz, J; Simon, K; Velasco, M; Vila, J, 2002) |
| "This study aimed to evaluate the efficacy and safety of oral antibacterial treatment with fluoroquinilone for acute uncomplicated pyelonephritis Thirteen female patients with acute uncomplicated pyelonephritis were treated with oral fluoroquinilone (ciprofloxacin; CPFX)." | 3.71 | Efficacy of a 14-day course of oral ciprofloxacin therapy for acute uncomplicated pyelonephritis. ( Hirose, T; Hisasue, SI; Itoh, N; Kato, R; Kunishima, Y; Matsukawa, M; Satoh, T; Shimizu, T; Takagi, S; Takahashi, S; Tsukamoto, T, 2001) |
| "The influence of fever on the pharmacokinetics of ciprofloxacin was investigated in seven patients with acute febrile diseases." | 3.70 | Influence of fever on the pharmacokinetics of ciprofloxacin. ( Belic, A; Beovic, B; Grabnar, I; Karba, R; Marolt-Gomiscek, M; Mrhar, A; Zupancic, T, 1999) |
| "We report a 67 years old diabetic female that received ciprofloxacin for an acute pyelonephritis." | 3.69 | [Tenosynovitis caused by ciprofloxacin. Clinical case]. ( Guzmán, L; Lara, R; Wainstein, E, 1994) |
| " In a murine model of hematogenous pyelonephritis, the in vivo efficacies of levofloxacin and ciprofloxacin were evaluated against two methicillin-susceptible and two methicillin-resistant S." | 3.69 | In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains. ( Barrett, JF; Frosco, MB; Kulwich, BA; Licata, L; Melton, JL; Stewart, FP, 1996) |
| "As urinary tract infections in immunosuppressed renal transplant patients present a major therapeutic problem for clinicians in charge of renal units, the efficacy of the antibiotic ciprofloxacin in such cases was tested in this study." | 3.68 | Treatment of urinary tract infections with ciprofloxacin after renal transplantation. ( Alivanis, P; Dioudis, C; Grekas, D; Thanos, V; Tourkantonis, A, 1993) |
| "The ciprofloxacin efficacy was compared to that of tobramycin in an Escherichia coli pyelonephritis model in rat." | 3.68 | Treatment of experimental Escherichia coli pyelonephritis in rat by ciprofloxacin in comparison with tobramycin. ( Grise, G; Le Boete, I; Lecomte, F; Lemeland, JF; Thauvin-Eliopoulos, C, 1990) |
| "Two quinolones, fleroxacin and ofloxacin were used as oral treatment in a model of experimental pyelonephritis in rats." | 3.67 | Comparative studies of fleroxacin and ofloxacin in experimental pyelonephritis. ( Ritzerfeld, W, 1988) |
| "The therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 was compared in alloxan-induced diabetic mice with experimental respiratory and urinary tract infections." | 3.67 | Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice. ( Nishino, T; Obana, Y, 1988) |
| "Five antimicrobial agents, ciprofloxacin, ticarcillin, piperacillin, aztreonam and gentamicin, were compared both in vitro (MIC's, time-kill studies) and in vivo, in the treatment of experimental Proteus mirabilis pyelonephritis in mice." | 3.67 | Comparative activities of five antimicrobial agents in experimental Proteus pyelonephritis in mice. ( Maclaren, DM; Peerbooms, PG, 1987) |
| "The efficacy and safety of two oral dosing regimens of gatifloxacin were compared to ciprofloxacin in the treatment of complicated urinary tract infection in a randomised, double-blind multi-centre trial." | 2.71 | Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. ( Ankel-Fuchs, D; Bartnicki, A; Bischoff, W; Hanus, M; Milutinovic, S; Naber, KG; Schönwald, S; van Belle, F; Weitz, P, 2004) |
| "We present an interesting case of Legionnaires' disease masquerading as acute pyelonephritis, with complete absence of respiratory symptoms on admission." | 1.42 | A rare presentation of Legionnaires' disease. ( Banerjee, A; Delicata, M, 2015) |
| "Ciprofloxacin was stopped and her pain quickly resolved." | 1.40 | Ciprofloxacin-induced tendinopathy of the gluteal tendons. ( Aronowitz, P; Shimatsu, K; Sim, H; Subramaniam, S, 2014) |
| "Treatment by ciprofloxacin (15 mg." | 1.29 | Suppression of renal scarring by prednisolone combined with ciprofloxacin in ascending pyelonephritis in rats. ( Haraoka, M; Kubo, S; Kumazawa, J; Matsumoto, T; Takahashi, K; Tanaka, M, 1994) |
| "Ciprofloxacin was tested in the acute and chronic experimental E." | 1.27 | [Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats]. ( Boness, J; Marre, R; Schulz, E; Tietgen, K, 1986) |
| "Ciprofloxacin was 1 to 3 twofold dilutions more active than A-61827 against these gram-negative bacteria." | 1.27 | A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. ( Bower, RR; Chu, DT; Fernandes, PB; Hanson, CW; Hardy, DJ; Ramer, NR; Stamm, JM; Swanson, RN, 1988) |
| "Temafloxacin hydrochloride was as active as ciprofloxacin and difloxacin against staphylococci and as active as ciprofloxacin and 2 twofold dilutions more active than difloxacin against streptococci." | 1.27 | Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Hanson, CW; Hardy, DJ; Hensey, DM; Ramer, NR; Swanson, RN, 1987) |
| "Norfloxacin was ineffective at 200 mg/kg per day against E." | 1.27 | In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones. ( Bower, RR; Chu, DT; Fernandes, PB; Jarvis, KP; Ramer, NR; Shipkowitz, N, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (13.92) | 18.7374 |
| 1990's | 18 (22.78) | 18.2507 |
| 2000's | 24 (30.38) | 29.6817 |
| 2010's | 24 (30.38) | 24.3611 |
| 2020's | 2 (2.53) | 2.80 |
| Authors | Studies |
|---|---|
| Dunne, MW | 1 |
| Aronin, SI | 1 |
| Das, AF | 1 |
| Akinapelli, K | 1 |
| Breen, J | 1 |
| Zelasky, MT | 1 |
| Puttagunta, S | 1 |
| Neguse, S | 1 |
| Bosch-Nicolau, P | 1 |
| Falcó, V | 1 |
| Viñado, B | 1 |
| Andreu, A | 1 |
| Len, O | 1 |
| Almirante, B | 1 |
| Pigrau, C | 1 |
| Wagenlehner, F | 1 |
| Nowicki, M | 1 |
| Bentley, C | 1 |
| Lückermann, M | 1 |
| Wohlert, S | 1 |
| Fischer, C | 1 |
| Vente, A | 1 |
| Naber, K | 1 |
| Dalhoff, A | 1 |
| Vogler, S | 1 |
| Pavich, E | 1 |
| Cattrall, JWS | 1 |
| Robinson, AV | 1 |
| Kirby, A | 1 |
| Fadel, MG | 1 |
| Louis, C | 1 |
| Tay, A | 1 |
| Bolgeri, M | 1 |
| Truong, WR | 1 |
| Won, KJ | 1 |
| Yamaki, J | 1 |
| Guillard, T | 1 |
| Cambau, E | 1 |
| Chau, F | 1 |
| Massias, L | 1 |
| de Champs, C | 1 |
| Fantin, B | 1 |
| Fagan, M | 1 |
| Lindbæk, M | 1 |
| Reiso, H | 1 |
| Berild, D | 1 |
| Park, KH | 1 |
| Oh, WS | 1 |
| Kim, ES | 2 |
| Park, SW | 2 |
| Hur, JA | 1 |
| Kim, YK | 1 |
| Moon, C | 1 |
| Lee, JH | 1 |
| Lee, CS | 1 |
| Kim, BN | 1 |
| Shimatsu, K | 1 |
| Subramaniam, S | 1 |
| Sim, H | 1 |
| Aronowitz, P | 1 |
| Delicata, M | 1 |
| Banerjee, A | 1 |
| Pasiechnikov, S | 1 |
| Buchok, O | 1 |
| Sheremeta, R | 1 |
| Banyra, O | 1 |
| Vadekeetil, A | 1 |
| Saini, H | 1 |
| Chhibber, S | 1 |
| Harjai, K | 1 |
| Fox, MT | 1 |
| Melia, MT | 1 |
| Same, RG | 1 |
| Conley, AT | 1 |
| Tamma, PD | 1 |
| Corvec, S | 1 |
| Lepelletier, D | 1 |
| Reynaud, A | 1 |
| Dauvergne, S | 1 |
| Giraudeau, C | 1 |
| Caroff, N | 1 |
| Tuccori, M | 1 |
| Guidi, B | 1 |
| Carulli, G | 1 |
| Blandizzi, C | 1 |
| Del Tacca, M | 1 |
| Di Paolo, M | 1 |
| Talan, DA | 2 |
| Krishnadasan, A | 1 |
| Abrahamian, FM | 1 |
| Stamm, WE | 1 |
| Moran, GJ | 1 |
| Cholongitas, E | 1 |
| Georgousaki, C | 1 |
| Spyrou, S | 1 |
| Katsogridakis, K | 1 |
| Dasenaki, M | 1 |
| Lee, SS | 1 |
| Kim, Y | 1 |
| Chung, DR | 1 |
| Caliskan, B | 1 |
| Guven, A | 1 |
| Ozler, M | 1 |
| Cayci, T | 1 |
| Ozcan, A | 1 |
| Bedir, O | 1 |
| Surer, I | 1 |
| Korkmaz, A | 1 |
| Lim, SK | 2 |
| Park, IW | 1 |
| Lee, WG | 1 |
| Kim, HK | 1 |
| Choi, YH | 1 |
| Jichlinski, P | 1 |
| Jeon, JH | 1 |
| Kim, K | 1 |
| Han, WD | 1 |
| Song, SH | 1 |
| Park, KU | 1 |
| Rhee, JE | 1 |
| Song, KH | 1 |
| Park, WB | 1 |
| Kim, NJ | 1 |
| Oh, MD | 1 |
| Kim, HB | 1 |
| Shin, J | 1 |
| Kim, J | 1 |
| Wie, SH | 1 |
| Cho, YK | 1 |
| Shin, SY | 1 |
| Yeom, JS | 1 |
| Lee, JS | 1 |
| Kweon, KT | 1 |
| Lee, H | 1 |
| Cheong, HJ | 1 |
| Park, SH | 1 |
| Park, DW | 1 |
| Ryu, SY | 1 |
| Chung, MH | 1 |
| Yoo, S | 1 |
| Pai, H | 1 |
| Sandberg, T | 1 |
| Skoog, G | 1 |
| Hermansson, AB | 1 |
| Kahlmeter, G | 1 |
| Kuylenstierna, N | 1 |
| Lannergård, A | 1 |
| Otto, G | 1 |
| Settergren, B | 1 |
| Ekman, GS | 1 |
| Nicolle, LE | 2 |
| Ortega, M | 1 |
| Marco, F | 1 |
| Soriano, A | 1 |
| Almela, M | 1 |
| Martínez, JA | 1 |
| Pitart, C | 1 |
| Mensa, J | 2 |
| Pittet, R | 1 |
| Malinverni, R | 1 |
| Vila, J | 1 |
| Simon, K | 1 |
| Ruiz, J | 1 |
| Horcajada, JP | 1 |
| Velasco, M | 1 |
| Barranco, M | 1 |
| Moreno, A | 1 |
| Song, JX | 1 |
| Wassell, JT | 1 |
| Oguz, Y | 1 |
| Doganci, L | 1 |
| Bulucu, F | 1 |
| Can, C | 1 |
| Oktenli, C | 1 |
| Yenicesu, M | 1 |
| Vural, A | 1 |
| Klimberg, IW | 1 |
| Song, J | 1 |
| Kowalsky, SF | 1 |
| Church, DA | 1 |
| Waugh, J | 1 |
| Keating, GM | 1 |
| Naber, KG | 1 |
| Bartnicki, A | 1 |
| Bischoff, W | 1 |
| Hanus, M | 1 |
| Milutinovic, S | 1 |
| van Belle, F | 1 |
| Schönwald, S | 1 |
| Weitz, P | 1 |
| Ankel-Fuchs, D | 1 |
| Pertel, PE | 1 |
| Haverstock, D | 1 |
| Aksu, B | 1 |
| Inan, M | 1 |
| Kanter, M | 1 |
| Oz Puyan, F | 1 |
| Uzun, H | 1 |
| Durmus-Altun, G | 1 |
| Gurcan, S | 1 |
| Aydin, S | 1 |
| Ayvaz, S | 1 |
| Pul, M | 1 |
| Klausner, HA | 1 |
| Brown, P | 1 |
| Peterson, J | 3 |
| Kaul, S | 3 |
| Khashab, M | 3 |
| Fisher, AC | 2 |
| Kahn, JB | 3 |
| Fisher, A | 1 |
| Klesel, N | 1 |
| Geweniger, KH | 1 |
| Koletzki, P | 1 |
| Isert, D | 1 |
| Limbert, M | 1 |
| Markus, A | 1 |
| Riess, G | 1 |
| Schramm, H | 1 |
| Iyer, P | 1 |
| George, J | 1 |
| Chakravarthy, S | 1 |
| John, GT | 1 |
| Jacob, CK | 1 |
| Lara, R | 1 |
| Wainstein, E | 1 |
| Guzmán, L | 1 |
| Bach, D | 1 |
| van den Berg-Segers, A | 1 |
| Hübner, A | 1 |
| van Breukelen, G | 1 |
| Cesana, M | 1 |
| Plétan, Y | 1 |
| Haraoka, M | 1 |
| Matsumoto, T | 1 |
| Takahashi, K | 1 |
| Kubo, S | 1 |
| Tanaka, M | 1 |
| Kumazawa, J | 1 |
| McDonald, GR | 1 |
| Grekas, D | 1 |
| Thanos, V | 1 |
| Dioudis, C | 1 |
| Alivanis, P | 1 |
| Tourkantonis, A | 1 |
| Bailey, RR | 2 |
| Begg, EJ | 1 |
| Smith, AH | 1 |
| Robson, RA | 2 |
| Lynn, KL | 2 |
| Chambers, ST | 1 |
| Barclay, ML | 1 |
| Hornibrook, J | 1 |
| Frosco, MB | 1 |
| Melton, JL | 1 |
| Stewart, FP | 1 |
| Kulwich, BA | 1 |
| Licata, L | 1 |
| Barrett, JF | 1 |
| Küchle, C | 1 |
| Abele-Horn, M | 1 |
| Menninger, M | 1 |
| Held, E | 1 |
| Heesemann, J | 1 |
| Richard, GA | 1 |
| Klimberg, IN | 1 |
| Fowler, CL | 1 |
| Callery-D'Amico, S | 1 |
| Kim, SS | 1 |
| Mombelli, G | 1 |
| Pezzoli, R | 1 |
| Pinoja-Lutz, G | 1 |
| Monotti, R | 1 |
| Marone, C | 1 |
| Franciolli, M | 1 |
| Caron, F | 1 |
| Beovic, B | 1 |
| Mrhar, A | 1 |
| Karba, R | 1 |
| Zupancic, T | 1 |
| Grabnar, I | 1 |
| Belic, A | 1 |
| Marolt-Gomiscek, M | 1 |
| Lee, CH | 1 |
| Cheung, RT | 1 |
| Chan, TM | 1 |
| Rosenbaum, D | 1 |
| Luther, S | 1 |
| Krist, A | 1 |
| Saint, F | 1 |
| Gueguen, G | 1 |
| Biserte, J | 1 |
| Fontaine, C | 1 |
| Mazeman, E | 1 |
| Le Conte, P | 1 |
| Simon, N | 1 |
| Bourrier, P | 1 |
| Merit, JB | 1 |
| Lebrin, P | 1 |
| Bonnieux, J | 1 |
| Potel, G | 1 |
| Baron, D | 1 |
| Howarth, FH | 1 |
| Takahashi, S | 1 |
| Hirose, T | 1 |
| Satoh, T | 1 |
| Kato, R | 1 |
| Hisasue, SI | 1 |
| Takagi, S | 1 |
| Shimizu, T | 1 |
| Kunishima, Y | 1 |
| Matsukawa, M | 1 |
| Itoh, N | 1 |
| Tsukamoto, T | 1 |
| Loran, OB | 1 |
| Pushkar', DIu | 1 |
| Rasner, PI | 1 |
| Cox, CE | 1 |
| Marbury, TC | 1 |
| Pittman, WG | 1 |
| Brown, GL | 1 |
| Auerbach, SM | 1 |
| Fox, BC | 1 |
| Yang, JY | 1 |
| Peddie, BA | 1 |
| Smith, A | 1 |
| Nagappan, R | 1 |
| Kletchko, S | 1 |
| Curran, KA | 1 |
| Peterson, JC | 1 |
| Croker, BP | 1 |
| Drane, WE | 1 |
| Tisher, CC | 1 |
| Lecomte, F | 1 |
| Thauvin-Eliopoulos, C | 1 |
| Le Boete, I | 1 |
| Grise, G | 1 |
| Lemeland, JF | 1 |
| Guibert, J | 1 |
| Destrée, D | 1 |
| Konopka, C | 1 |
| Acar, J | 1 |
| Van Poppel, H | 1 |
| Wegge, M | 1 |
| Dammekens, H | 1 |
| Chysky, V | 1 |
| Tietgen, K | 1 |
| Schulz, E | 1 |
| Boness, J | 1 |
| Marre, R | 1 |
| Gargallo, D | 1 |
| Moros, M | 1 |
| Coll, R | 1 |
| Esteve, M | 1 |
| Parés, J | 1 |
| Xicota, MA | 1 |
| Guinea, J | 1 |
| Ritzerfeld, W | 1 |
| Obana, Y | 1 |
| Nishino, T | 1 |
| Peerbooms, PG | 1 |
| Maclaren, DM | 1 |
| Fernandes, PB | 3 |
| Chu, DT | 3 |
| Swanson, RN | 2 |
| Ramer, NR | 3 |
| Hanson, CW | 2 |
| Bower, RR | 3 |
| Stamm, JM | 1 |
| Hardy, DJ | 2 |
| Hensey, DM | 1 |
| Jarvis, KP | 1 |
| Shipkowitz, N | 1 |
| Tolkoff-Rubin, NE | 1 |
| Rubin, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective, Phase 3, Randomized, Multi-center, Double-blind, Double-dummy Study of Efficacy, Tolerability & Safety of Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Treatment of cUTI in Adults[NCT03357614] | Phase 3 | 1,395 participants (Actual) | Interventional | 2018-09-18 | Completed | ||
| A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation.[NCT01928433] | Phase 2 | 225 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| A Multicenter, Double-blind, Randomized Study to Compare the Efficacy and Safety of Levofloxacin 750 mg Once Daily for Five Days Versus Ciprofloxacin Twice Daily for Ten Days in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis[NCT00210886] | Phase 3 | 1,109 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)[NCT02650518] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Microbiologic success is defined as demonstrating <1000 CFU/mL of the baseline urpathogen by quantitative urine culture (NCT03357614)
Timeframe: Day 21 +/- 1 day
| Intervention | Participants (Count of Participants) |
|---|---|
| Sulopenem | 316 |
| Ertapenem | 343 |
Clinical success is defined as complete resolution of cUTI symptoms present at study entry and no new cUTI symptoms; microbiologic success is defined as eradication of the bacterial pathogen found at study entry (reduced to <1000 CFU/mL) (NCT03357614)
Timeframe: Day 21 +/- 1 day
| Intervention | Participants (Count of Participants) |
|---|---|
| Sulopenem | 301 |
| Ertapenem | 325 |
"The primary endpoint of this study is the clinical and microbiological response of patients with cUTI or pyelonephritis to treatment with finafloxacin for 5 days versus finafloxacin for 10 days versus ciprofloxacin for 10 days as a reference comparator at the Test of Cure (ToC) visit (Day 17) in the microbiological intent-to-treat population (micro-ITT population).~Clinical response is defined as resolution of the symptoms of cUTI present at trial entry and no new symptoms developed. Microbiological response is defined as elimination or reduction of study entry pathogens to ≤ 10e3 CFU/mL on urine culture. The clinical and microbiological response will be assessed for each group on Day 17 and will be compared between the three groups to assess the efficacy in each group." (NCT01928433)
Timeframe: Day 17
| Intervention | Participants (Count of Participants) |
|---|---|
| Finafloxacin 5 Days | 45 |
| Finafloxacin 10 Days | 46 |
| Ciprofloxacin 10 Days | 35 |
The clinical and microbiological response as the efficacy parameter will be assessed for each group and will be compared between the three groups. Separate analyses will be performed for all time points for the clinical and microbiological responders and compared also between the different groups. (NCT01928433)
Timeframe: Day 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Finafloxacin 5 Days | 47 |
| Finafloxacin 10 Days | 42 |
| Ciprofloxacin 10 Days | 34 |
The clinical and microbiological response as the efficacy parameter will be assessed for each group and will be compared between the three groups. Separate analyses will be performed for all time points for the clinical and microbiological responders and compared also between the different groups. (NCT01928433)
Timeframe: Day 10
| Intervention | Participants (Count of Participants) |
|---|---|
| Finafloxacin 5 Days | 49 |
| Finafloxacin 10 Days | 49 |
| Ciprofloxacin 10 Days | 44 |
The clinical and microbiological response as the efficacy parameter will be assessed for each group and will be compared between the three groups. Separate analyses will be performed for all time points for the clinical and microbiological responders and compared also between the different groups. (NCT01928433)
Timeframe: Day 3
| Intervention | Participants (Count of Participants) |
|---|---|
| Finafloxacin 5 Days | 39 |
| Finafloxacin 10 Days | 40 |
| Ciprofloxacin 10 Days | 33 |
This study will evaluate the safety of the different regimens of finafloxacin. The safety outcome measures assessed are the following: vital signs, physical examinations, ECGs, haematology, biochemistry, urinalysis, adverse events and serious adverse events. Adverse events and serious adverse events will be documented throughout the study for each group (including comparator group and the incidence and severity of their occurrence will be compared between all groups. The results of all other safety outcome measures will be compared with the baseline values of each group to determine if significant changes occurred during the course of the study within one group. The results at the different visits will also be compared between the groups to identify significant differences between the 3 treatment groups. (NCT01928433)
Timeframe: Screening to day 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Finafloxacin 5 Days | 7 |
| Finafloxacin 10 Days | 2 |
| Ciprofloxacin 10 Days | 4 |
This study will evaluate the safety of the different regimens of finafloxacin. The safety outcome measures assessed are the following: vital signs, physical examinations, ECGs, haematology, biochemistry, urinalysis, adverse events and serious adverse events. Adverse events and serious adverse events will be documented throughout the study for each group (including comparator group and the incidence and severity of their occurrence will be compared between all groups. The results of all other safety outcome measures will be compared with the baseline values of each group to determine if significant changes occurred during the course of the study within one group. The results at the different visits will also be compared between the groups to identify significant differences between the 3 treatment groups. (NCT01928433)
Timeframe: Screening to Day 24
| Intervention | Treatment-emergent AEs (Number) |
|---|---|
| Finafloxacin 5 Days | 70 |
| Finafloxacin 10 Days | 51 |
| Ciprofloxacin 10 Days | 70 |
7 reviews available for ciprofloxacin and Pyelonephritis
| Article | Year |
|---|---|
A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis.
Topics: Acute Disease; Administration, Oral; Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Drug Comb | 2018 |
[Infectious diseases].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Diabetic Foot; Endocarditis; Humans; Infections; Plant Extract | 2013 |
Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis.
Topics: Administration, Oral; Anti-Bacterial Agents; Ciprofloxacin; Delayed-Action Preparations; Gram-Negati | 2004 |
Bilateral emphysematous pyelonephritis responding to nonsurgical management.
Topics: Cefuroxime; Ciprofloxacin; Diabetic Nephropathies; Drug Therapy, Combination; Emphysema; Escherichia | 1995 |
[Mycoplasma hominis. A rare causative agent of acute pyelonephritis].
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Doxycycline; Drug | 1997 |
[Current role of aminoglycosides in the treatment of acute pyelonephritis].
Topics: Acute Disease; Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefadroxil | 1998 |
New approaches to the treatment of urinary tract infection.
Topics: Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Humans; Male; Pyelonephritis; Ur | 1987 |
16 trials available for ciprofloxacin and Pyelonephritis
| Article | Year |
|---|---|
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.
Topics: Adult; Anti-Bacterial Agents; Bacteriuria; Ciprofloxacin; Ertapenem; Humans; Pyelonephritis; Urinary | 2023 |
Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin | 2018 |
Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Bacteriuria; Ciprofloxacin; Community-Acquired In | 2012 |
Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Del | 2004 |
Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections.
Topics: Bacterial Infections; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2004 |
A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Double-Blind Method; Drug Administ | 2007 |
Identification and pretherapy susceptibility of pathogens in patients with complicated urinary tract infection or acute pyelonephritis enrolled in a clinical study in the United States from November 2004 through April 2006.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Ciprof | 2007 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Do | 2008 |
Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; C | 1995 |
Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis.
Topics: Acute Disease; Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxa | 1996 |
Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Fem | 1998 |
Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Infective Agents, | 1999 |
[Acute pyelonephritis. Randomized multicenter double-blind study comparing ciprofloxacin with combined ciprofloxacin and tobramycin].
Topics: Acute Disease; Adult; Aged; Ciprofloxacin; Double-Blind Method; Drug Therapy, Combination; Escherich | 2001 |
[Tavanik effectiveness and safety in the treatment of urinary tract infection complications].
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Male; Middle Aged; Of | 2001 |
A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Double-Blind Metho | 2002 |
Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Ciprofloxacin; Escherichia coli Infect | 1992 |
56 other studies available for ciprofloxacin and Pyelonephritis
| Article | Year |
|---|---|
Pyelonephritis.
Topics: Acute Disease; Adult; Ampicillin; Anti-Bacterial Agents; Ciprofloxacin; Female; Fluid Therapy; Fluor | 2020 |
A Cohort Study of Risk Factors That Influence Empirical Treatment of Patients with Acute Pyelonephritis.
Topics: Acute Disease; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ce | 2017 |
Pyelonephritis treatment in the community emergency department: Cephalosporins vs. first-line agents.
Topics: Adult; Anti-Bacterial Agents; Cefdinir; Cephalexin; Ciprofloxacin; Drug Resistance, Bacterial; Emerg | 2018 |
Obstructive urosepsis secondary to ureteric herniation into the sciatic foramen.
Topics: Abdominal Pain; Acute Disease; Aged; Anti-Bacterial Agents; Ciprofloxacin; Female; Hernia; Humans; H | 2018 |
Antibiotic selection and isolate susceptibility profile in patients who failed ciprofloxacin or TMP-SMX for pyelonephritis.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Emergency Service, Hospital; Humans; Pyeloneph | 2019 |
Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; Drug Administrati | 2013 |
A simple intervention to reduce inappropriate ciprofloxacin prescribing in the emergency department.
Topics: Amdinocillin; Anti-Bacterial Agents; Ciprofloxacin; Cystitis; Emergency Service, Hospital; Female; H | 2014 |
Factors associated with ciprofloxacin- and cefotaxime-resistant Escherichia coli in women with acute pyelonephritis in the emergency department.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Drug Resistance, Multiple, Ba | 2014 |
Ciprofloxacin-induced tendinopathy of the gluteal tendons.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Buttocks; Ciprofloxacin; Female; Humans; Magnetic Reson | 2014 |
A rare presentation of Legionnaires' disease.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Ciprofloxacin; Community-Acquired Infections; Diagnosis, | 2015 |
Empirical treatment in patients with acute obstructive pyelonephritis.
Topics: Acute Disease; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Escherichia coli; Female; Humans; | 2015 |
Exploiting the antivirulence efficacy of an ajoene-ciprofloxacin combination against Pseudomonas aeruginosa biofilm associated murine acute pyelonephritis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Biofilms; Ciprofloxacin; Disease Models, Animal; Dis | 2016 |
A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Drug Administration Sch | 2017 |
In vivo selection of an Escherichia coli isolate highly resistant to ciprofloxacin and ceftazidime: role of a 4-bp duplication in acrR and ampC overexpression.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Ciprofloxacin; Drug Resista | 2008 |
Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Ciprofloxacin; Diagnostic Errors; Fatal | 2008 |
Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross-Sectional Studies; Drug Resistance, | 2008 |
Stevens-Johnson syndrome related to ciprofloxacin, possibly enhanced by overadministration of levothyroxine.
Topics: Aged; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactio | 2009 |
Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Cohort Studies; Community-Acquired Infection | 2011 |
Ozone therapy prevents renal inflammation and fibrosis in a rat model of acute pyelonephritis.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Aspartate Aminotransferases; Calcitonin; Ciprofloxaci | 2011 |
Change of antimicrobial susceptibility among Escherichia coli strains isolated from female patients with community-onset acute pyelonephritis.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Dru | 2012 |
[Urology in 2011].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Anti-Bacterial Agents; Anti-Infective Ag | 2012 |
Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high.
Topics: Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Esc | 2012 |
Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escher | 2012 |
Minimum antimicrobial treatment for acute pyelonephritis.
Topics: Anti-Infective Agents; Bacteriuria; Ciprofloxacin; Female; Humans; Pyelonephritis | 2012 |
Epidemiology and prognostic determinants of bacteremic acute pyelonephritis in women.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Humans; Inappropriate P | 2013 |
Are quinolone-resistant uropathogenic Escherichia coli less virulent?
Topics: Anti-Infective Agents; Bacterial Toxins; Ciprofloxacin; Cystitis; Cytotoxins; Drug Resistance, Micro | 2002 |
Sample size for K 2x2 tables in equivalence studies using Cochran's statistic.
Topics: Analysis of Variance; Anti-Infective Agents; Ciprofloxacin; Clinical Trials as Topic; Confidence Int | 2003 |
Acute pyelonephritis causing acute renal allograft dysfunction.
Topics: Acute Disease; Anti-Infective Agents; Ciprofloxacin; Female; Graft Rejection; Humans; Kidney; Kidney | 2002 |
Risk factors for a poor outcome after therapy for acute pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Diabetes | 2006 |
The effects of methylene blue on renal scarring due to pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Cicatrix; Ciprofloxacin; Disease Mod | 2007 |
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals.
Topics: Abscess; Animals; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Female; Granuloma; Kle | 1995 |
[Tenosynovitis caused by ciprofloxacin. Clinical case].
Topics: Aged; Ciprofloxacin; Female; Humans; Pyelonephritis; Tenosynovitis | 1994 |
Suppression of renal scarring by prednisolone combined with ciprofloxacin in ascending pyelonephritis in rats.
Topics: Animals; Cicatrix; Ciprofloxacin; Drug Administration Schedule; Drug Therapy, Combination; Female; K | 1994 |
Endocarditis after ciprofloxacin therapy for enterococcal pyelonephritis with bacteremia.
Topics: Aged; Bacteremia; Ciprofloxacin; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus fa | 1993 |
Treatment of urinary tract infections with ciprofloxacin after renal transplantation.
Topics: Administration, Oral; Adult; Bacterial Infections; Bacteriuria; Ciprofloxacin; Cystitis; Female; Hum | 1993 |
In vivo efficacies of levofloxacin and ciprofloxacin in acute murine hematogenous pyelonephritis induced by methicillin-susceptible and-resistant Staphylococcus aureus strains.
Topics: Acute Disease; Animals; Anti-Infective Agents; Ciprofloxacin; Colony Count, Microbial; Female; Kidne | 1996 |
Influence of fever on the pharmacokinetics of ciprofloxacin.
Topics: Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Female; Fever; Humans; Male; Middle Aged; Pyelone | 1999 |
Ciprofloxacin-induced oral facial dyskinesia in a patient with normal liver and renal function.
Topics: Anti-Infective Agents; Ciprofloxacin; Dyskinesia, Drug-Induced; Face; Female; Humans; Middle Aged; P | 2000 |
Is a 7-day course of ciprofloxacin effective in the treatment of uncomplicated pyelonephritis in women?
Topics: Adolescent; Adult; Anti-Infective Agents; Anti-Infective Agents, Urinary; Ciprofloxacin; Escherichia | 2000 |
[Rupture of the patellar ligament one month after treatment with fluoroquinolone].
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Humans; Knee Injuries; Male; Patellar Ligament; Pyelone | 2000 |
Acute pyelonephritis. A case discussion of primary care issues.
Topics: Acute Disease; Adult; Anti-Infective Agents; Ciprofloxacin; Female; Humans; Nurse Practitioners; Pri | 2000 |
Study finds surprising amount of bacterial resistance to standard antibiotic treatment of kidney infections.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Health Care Cost | 2000 |
Efficacy of a 14-day course of oral ciprofloxacin therapy for acute uncomplicated pyelonephritis.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Infective Agents; Ciprofloxacin; Drug Adminis | 2001 |
Bilateral emphysematous pyelonephritis resolving to medical therapy.
Topics: Cilastatin; Cilastatin, Imipenem Drug Combination; Ciprofloxacin; Drug Combinations; Emphysema; Esch | 1992 |
Gallium scan in the diagnosis and treatment of renal malacoplakia.
Topics: Ciprofloxacin; Diagnosis, Differential; Escherichia coli Infections; Female; Gallium Radioisotopes; | 1990 |
Treatment of experimental Escherichia coli pyelonephritis in rat by ciprofloxacin in comparison with tobramycin.
Topics: Animals; Ciprofloxacin; Drug Administration Schedule; Escherichia coli Infections; Injections, Intra | 1990 |
Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Ciprofloxacin; Cystitis; Drug | 1986 |
Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis.
Topics: Anti-Infective Agents; Catheters, Indwelling; Ciprofloxacin; Cystitis; Enterobacteriaceae Infections | 1986 |
[Ciprofloxacin and cefotaxim: pharmacokinetic and therapeutic effectiveness in E. coli pyelonephritis in rats].
Topics: Acute Disease; Animals; Anti-Infective Agents, Urinary; Cefotaxime; Chronic Disease; Ciprofloxacin; | 1986 |
Activity of E-3846, a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats.
Topics: Animals; Anti-Infective Agents; Anti-Infective Agents, Urinary; Bacteria; Chemical Phenomena; Chemis | 1988 |
Comparative studies of fleroxacin and ofloxacin in experimental pyelonephritis.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli; Fleroxacin; Half-Life; Klebsiella; | 1988 |
Therapeutic efficacy of ofloxacin, ciprofloxacin and NY-198 in experimentally infected normal and alloxan-induced diabetic mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Diabetes Mellitus, Experimental; Female; Fluoroquinol | 1988 |
Comparative activities of five antimicrobial agents in experimental Proteus pyelonephritis in mice.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Male; Mice; Microbial Sensitivity Tests; Proteus Infe | 1987 |
A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria.
Topics: Abscess; Animals; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacteroides Infecti | 1988 |
Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Microbial; Female; Fluoroquinolones; | 1987 |
In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enterobacteriaceae In | 1986 |